221 % Kursgewinn:
Und jetzt kommt der größte Trigger: FDA-Entscheidung steht bevor
Anzeige
Original-Research

tonies SE (von NuWays AG): Buy 29.08.2025, 09:00 Uhr von dpa-AFX Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
tonies Registered (A) 10,78 EUR +0,56 % Gettex

^

Original-Research: tonies SE - from NuWays AG

29.08.2025 / 09:00 CET/CEST

Dissemination of a Research, transmitted by EQS News - a service of EQS

Group.

The issuer is solely responsible for the content of this research. The

result of this research does not constitute investment advice or an

invitation to conclude certain stock exchange transactions.

---------------------------------------------------------------------------

Classification of NuWays AG to tonies SE

Company Name: tonies SE

ISIN: LU2333563281

Reason for the research: Update

Recommendation: Buy

from: 29.08.2025

Target price: EUR 11.00

Target price on sight of: 12 months

Last rating change:

Analyst: Henry Wendisch

tonies released a solid set of Q2 results but were impacted by growth

investments in light of the launch of TB2. In detail:

Q2 sales grew by 16% yoy to EUR 79m. Regionally, North America grew by 14% yoy

to EUR 31m (39% of group sales), whereas Rest of World maintained its strong

momentum and grew by 74% yoy to EUR 16m (21% of group sales) especially driven

by France, UK, Australia and New Zealand while DACH remained flat yoy at EUR

32m (40% of group sales). On a product group level, sales from tonies grew

by +22% yoy to EUR 60m on the back of 7% more units sold and a 14% higher ASP

of EUR 10.03, mainly thanks to price increases in the USA since May 2025. On

the other hand, the sales from tonieboxes declined by 14% yoy to EUR 15.8m

with ASP flat yoy and 14% less units sold, as retailers have reduced

inventory build up in anticipation of TB2.

On an H1 basis, which includes are more detailed profitability picture,

gross profit after licensing costs grew faster than sales by 29% yoy to EUR

104m (58.8% margin, up 4.1pp yoy) mainly thanks to lower relative COGS

(-3.6pp yoy sales ratio), but also due a better mix effect affecting

licensing costs (-0.4pp yoy). This effect is a result of the aforementioned

growth of tonies and decline of tonieboxes, as tonies in general carry a

much higher gross margin than tonieboxes but also benefitted from the price

increase (as of May 1st in the US). Consequently, contribution profit

expanded drastically by 38% yoy to EUR 76m (42.9% margin, up 5.6pp yoy) on the

back of further logistic efficiency gains due to better scale.

On the other hand, adj. EBITDA was nonetheless impacted by higher personell

costs (+27% yoy; 18.9% sales ratio, up 1pp yoy) which led to an adj. EBITDA

of at EUR 3.8m (-4% yoy; 2.1% margin, down 0.5pp yoy). This should stem mainly

from the personnel ramp up and incurred development costs of TB2.

Following more tariff clarity, tonies issued a FY 25 guidance. Sales are

expected to grow by more than 25% yoy (before FX) to above EUR 600m. Thereof,

NA should grow by 30% yoy. Adj. EBITDA margin is seen between 6.5-8.5% in

FY'25e.

A key highlight was launch of the "Toniebox 2" (TB2). Many new features

(e.g. "Tonieplay", sleep timer, sun alarm, .) are aimed to increase usage by

adding interactivity to the linear audio, thus increase lock in effects and

platform loyalty, which creates the basis for higher recurring revenues.

Moreover, TB2 doubles the addressable market by expanding the age-group to

1-9 (prev. 3-7 with TB1) in two ways: (1) the new "My First Tonies" are

especially designed and approved for toddlers, giving parents an earlier

touchpoint to get to know the tonies ecosystem and build trust with the

brand and (2) the interactive audio and games-like features of "Tonieplay"

(that only work on the TB2) gives parents in today's tech saturated

childhoods an opportunity to have a screen-free toy until the age of 9+, for

which age group screen-based toys are still not healthy. All in all, TB2 is

seen as the largest product innovation since the start in 2016, creates

strong up- and cross-selling opportunities and should thus play an important

role of continuing tonies' growth ahead.

Against this backdrop, we recommend to BUY with a PT of EUR 11.00, based on

DCF.

You can download the research here:

https://eqs-cockpit.com/c/fncls.ssp?u=3f6b9a1f527f488a6ef6a56033aac86f

For additional information visit our website:

https://www.nuways-ag.com/research-feed

Contact for questions:

NuWays AG - Equity Research

Web: www.nuways-ag.com

Email: research@nuways-ag.com

LinkedIn: https://www.linkedin.com/company/nuwaysag

Adresse: Mittelweg 16-17, 20148 Hamburg, Germany

++++++++++

Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss

bestimmter Börsengeschäfte.

Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben

analysierten Unternehmen befinden sich in der vollständigen Analyse.

++++++++++

---------------------------------------------------------------------------

The EQS Distribution Services include Regulatory Announcements,

Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com

---------------------------------------------------------------------------

2190414 29.08.2025 CET/CEST

°

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Werbung
Weiter aufwärts?
Kurzfristig positionieren
Ask: 1,65
Hebel: 6
mit moderatem Hebel
Smartbroker
Morgan Stanley
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: MN07B0. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer